DNDN: No earnings power until Provenge hits market

DNDN is an innovative company that developed Provenge to combat prostate cancer. It has been voted 17-0 as safe, but 13-4 to meet the guidelines of congressional approval. The 4 no votes had conflict of interests and we are beginning to see an outcry against two specific doctors. Protests held last year to approve the drug last year came to no avail, and protests this year are likely to do the same. There is much to controversy surrounding Provenge for it to be approved soon, and it is DNDN's only hope to becoming profitable. We have seen this current economic trend rip through CEGE,a stock I shorted previously. Hedge funds who completed capital placements into DNDN are eager to sell their shares and get out, many of them already in the red from the CEGE deal. In summary, with terrible fundamentals, 1 chance at profitability that looks grim, over sold and under owned issues Short it